StreetInsider.com News Articles

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

Thu, 16 Jul 2026 16:05:00 -0400

WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call.

Parties interested in participating by phone should register using this online form. After registering for

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

Thu, 16 Jul 2026 16:05:00 -0400

Parties interested in participating by phone should register using this online form. After registering for

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

Thu, 16 Jul 2026 16:05:00 -0400

Parties interested in participating by phone should register using this online form. After registering for

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

Thu, 16 Jul 2026 16:05:00 -0400

Parties interested in participating by phone should register using this online form. After registering for

Form SCHEDULE 13G/A TriSalus Life Sciences, Filed by: First Light Asset Management, LLC

Tue, 07 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260707/26742308.html

Form SCHEDULE 13G/A TriSalus Life Sciences, Filed by: First Light Asset Management, LLC

Tue, 07 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260707/26742308.html

Form 4 TriSalus Life Sciences, For: Jul 01 Filed by: Patience David

Mon, 06 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26735314.html

Form 4 TriSalus Life Sciences, For: Jul 01 Filed by: Patience David

Mon, 06 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26735314.html

Form 4 TriSalus Life Sciences, For: Jun 30 Filed by: Szela Mary T

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720583.html

Form 4 TriSalus Life Sciences, For: Jun 30 Filed by: Szela Mary T

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720583.html

Form 4 TriSalus Life Sciences, For: Jun 30 Filed by: Marshak Richard

Wed, 01 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26720507.html

Form 4 TriSalus Life Sciences, For: Jun 30 Filed by: Marshak Richard

Wed, 01 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26720507.html

Form 5 TriSalus Life Sciences, For: Dec 31 Filed by: Szela Mary T

Wed, 01 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26720520.html

Form 5 TriSalus Life Sciences, For: Dec 31 Filed by: Szela Mary T

Wed, 01 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26720520.html

Form 5 TriSalus Life Sciences, For: Dec 31 Filed by: Marshak Richard

Wed, 01 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26720491.html

Form 5 TriSalus Life Sciences, For: Dec 31 Filed by: Marshak Richard

Wed, 01 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26720491.html

Form 4 TriSalus Life Sciences, For: Jun 29 Filed by: Marshall Richard Henry

Mon, 29 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260629/26706961.html

Form 4 TriSalus Life Sciences, For: Jun 29 Filed by: Marshall Richard Henry

Mon, 29 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260629/26706961.html

Form 3 TriSalus Life Sciences, For: Jun 29 Filed by: Marshall Richard Henry

Mon, 29 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26706895.html

Form 3 TriSalus Life Sciences, For: Jun 29 Filed by: Marshall Richard Henry

Mon, 29 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26706895.html

Canaccord Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)

Thu, 25 Jun 2026 06:40:09 -0400

Canaccord analyst William Plovanic reiterated a Buy rating and $7.00 price target on TriSalus Life Sciences, Inc. (NASDAQ: TLSI).

The analyst commented: "This morning, TriSalus hosted a virtual KOL event focused on TriNav’s clinical and economic benefit in liver embolization. The event began with CEO Mary Szela providing an overview of the company’s mission, market opportunity, and TriNav’s differentiated technology. After Ms. Szela, Dr. Richard Marshall, the company’s Medical Director, reminded investors of TriNav’s real world evidence, which shows TriNav delivers strong clinical outcomes despite disproportionate use in sicker patients compared to other therapy options in healthier patients. The event was

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Wed, 10 Jun 2026 08:00:00 -0400

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions.

Leading interventional oncologist to share clinical experience and patient case examples

WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Wed, 10 Jun 2026 08:00:00 -0400

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions.

Leading interventional oncologist to share clinical experience and patient case examples

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Wed, 10 Jun 2026 08:00:00 -0400

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions.

Leading interventional oncologist to share clinical experience and patient case examples

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Wed, 10 Jun 2026 08:00:00 -0400

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions.

Leading interventional oncologist to share clinical experience and patient case examples